Advertisement

Case reports and case series from Lancet had significant impact on medical literature

Published:September 14, 2005DOI:https://doi.org/10.1016/j.jclinepi.2005.04.003

      Abstract

      Background and Objectives

      Case reports and case series are often the first evidence of innovative treatment, but clinical trials need to follow to substantiate this evidence. The objective of this article was to evaluate case reports or case series describing innovative treatment concerning their impact.

      Methods

      Case reports and case series (n ≤ 10) from a high-impact journal, The Lancet, published from 1 January 1996 to 30 June 1997, were evaluated according to predefined criteria. To assess publication impact, Pubmed, Science Citation Index, the Register of Current Controlled Clinical Trials, and the Cochrance Controlled Clinical Trials Register were searched.

      Results

      Sixty-four case reports and 39 case series were identified. They were cited in average 17 times (median 6,5; range 0–336). Twenty-Four follow-up trials were identified, nine in the register of current controlled clinical trials.

      Conclusion

      Case reports and case series can be well received, and have significant influence on subsequent literature and possibly on clinical practice. Many were followed by clinical trials. Often, though, they report rare conditions for which trials may not be feasible, and more or less explicitly transfer established treatment into other conditions. Overall, there is a strong publication bias favoring positive results, and opportunity should be created for publication of follow-up reports.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Feinstein A.R.
        • Horwitz R.I.
        Problems in the “evidence” of “evidence-based medicine.”.
        Am J Med. 1997; 103: 529-535
        • Moses L.E.
        The series of consecutive cases as a device for assessing outcomes of intervention.
        N Engl J Med. 1984; 311: 705-710
        • Jenicek M.
        Clinical case reporting in evidence-based medicine.
        Arnold, London2001
        • Vandenbroucke J.P.
        In defense of case reports and case series.
        Ann Intern Med. 2001; 134: 330-334
        • Greenhalgh T.
        • Taylor R.
        Papers that go beyond numbers (qualitative research).
        BMJ. 1997; 315: 740-743
        • Fraser S.W.
        • Greenhalgh T.
        Coping with complexity: educating for capability.
        BMJ. 2001; 323: 799-803
        • Greenhalgh T.
        Integrating qualitative research into evidence based practice.
        Endocrinol Metab Clin North Am. 2002; 31: 583-601
        • Enk A.H.
        • Knop J.
        Treatment of pemphigus vulgaris with mycophenolate mofetil.
        Lancet. 1997; 350: 494
        • Hohenleutner U.
        • Mohr V.D.
        • Michel S.
        • Landthaler M.
        Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum.
        Lancet. 1997; 350: 1748
        • Zimmer-Molsberger B.
        • Knauf W.
        • Thiel E.
        Mycophenolate mofetil for severe autoimmune haemolytic anemia.
        Lancet. 1997; 350: 1003-1004
        • Nowack R.
        • Birck R.
        • van der Woude F.J.
        Mycophenolate mofetil for systemic vasculitis and IgA nephropathy.
        Lancet. 1997; 349: 774
        • Bohm M.
        • Beissert S.
        • Schwarz T.
        • Metze D.
        • Luger T.
        Bullous pemphigoid treated with mycophenolate mofetil.
        Lancet. 1997; 349: 541
        • Conroy S.
        • Choonara I.
        • Impicciatore P.
        • Mohn A.
        • Arnell H.
        • Rane A.
        • et al.
        Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children.
        BMJ. 2000; 320: 79-82
        • Gottlieb J.J.
        • Washenik K.
        • Chachoua A.
        • Friedman-Kien A.
        Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
        Lancet. 1997; 350: 1363-1364
        • Goddard A.F.
        • Logan R.P.
        • Atherton J.C.
        • Jenkins D.
        • Spiller R.C.
        Healing of duodenal ulcer after eradication of Helicobacter heilmannii.
        Lancet. 1997; 349: 1815-1816
        • Vento S.
        • Cainelli F.
        • Renzini C.
        • Ghironzi G.
        • Concia E.
        Resolution of autoimmune hepatitis after bone-marrow transplantation.
        Lancet. 1996; 348: 544-545
        • Joske D.J.
        • Ma D.T.
        • Langlands D.R.
        • Owen E.T.
        Autologous bone-marrow transplantation for rheumatoid arthritis.
        Lancet. 1997; 350: 337-338
        • Brugger S.A.
        • Oesterreicher C.
        • Hofmann H.
        • Kalhs P.
        • Greinix H.T.
        • Muller C.
        Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor.
        Lancet. 1997; 349: 996-997
        • Lau G.K.
        • Liang R.
        • Lee C.K.
        • Lim W.L.
        Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation?.
        Lancet. 1997; 349: 1626-1627
        • Ringden O.
        • Lonnqvist B.
        • Holst M.
        12-year follow-up of allogeneic bone-marrow transplant for Langerhans' cell histiocytosis.
        Lancet. 1997; 349: 476
        • Guleria R.
        • Pande J.N.
        Endoscopic instillation of fungicide to treat aspergilloma.
        Lancet. 1996; 348: 621
        • Black N.
        Why we need observational studies to evaluate the effectiveness of health care.
        BMJ. 1996; 312: 1215-1218
        • Isner J.M.
        • Pieczek A.
        • Schainfeld R.
        • Blair R.
        • Haley L.
        • Asahara T.
        • et al.
        Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.
        Lancet. 1996; 348: 370-374
      1. Quigley EM. Presentation of a manuscript and an abstract. OMGE, Train the trainers, workshop material, Crete, 4-28-2001.

        • Joseph K.S.
        Quality of impact factors of general medical journals.
        BMJ. 2003; 326: 283
        • Joseph K.S.
        • Hoey J.
        CMAJ's impact factor: room for recalculation.
        CMAJ. 1999; 161: 977-978
        • Horton R.
        Medical editors trial amnesty.
        Lancet. 1997; 350: 756
        • Smith R.
        • Roberts I.
        An amnesty for unpublished trials.
        BMJ. 1997; 315: 622
        • Easterbrook P.J.
        • Berlin J.A.
        • Gopalan R.
        • Matthews D.R.
        Publication bias in clinical research.
        Lancet. 1991; 337: 867-872
        • Abel U.
        Bedeutung von Kasuistiken für die Wirksamkeitsüberprüfung medizinischer Therapien—meaning of case reports for testing the effectivness of medical therapy.
        in: Bühring M.K.F.H. Naturheilverfahren und unkonventionelle Medizinische Richtungen—natural cures and uncoventional medical orientations. Springer, Berlin1998: 1-12
        • Abel U.
        Erkenntnisgewinn mittels nichtrandomisierter Therapiestudien—gaining understanding through nonrandomised therapeutic studies.
        Ellipse. 1999; 15: 48-58
        • Moher D.
        • Jones A.
        • Lepage L.
        Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation.
        JAMA. 2001; 285: 1992-1995